Trav12n-1 Inhibitors
Trav12n-1 inhibitors are a class of chemical compounds that specifically target the Trav12n-1 protein or receptor, modulating its biological function by inhibiting its activity. These inhibitors typically operate by binding to the active site of the Trav12n-1 protein, preventing the interaction between the protein and its natural ligands or substrates. This competitive binding blocks the protein's normal role in biochemical processes. In addition to active-site binding, some Trav12n-1 inhibitors may also bind to allosteric sites, which are regions separate from the active site. When bound to these allosteric sites, the inhibitors induce conformational changes that disrupt the protein's structure and reduce or completely inhibit its activity. These interactions between the Trav12n-1 inhibitors and the protein are mediated by a variety of non-covalent forces, including hydrogen bonding, van der Waals interactions, hydrophobic effects, and ionic interactions, which together contribute to the stability and specificity of the inhibitor-protein complex.
The chemical structure of Trav12n-1 inhibitors can be highly diverse, with designs ranging from small organic molecules to larger, more complex frameworks. These inhibitors often feature aromatic rings, heterocyclic structures, and key functional groups such as hydroxyl, carboxyl, or amine groups, which enhance their ability to interact with specific regions of the Trav12n-1 protein. These functional groups enable important non-covalent interactions, such as hydrogen bonding or hydrophobic interactions, that stabilize the binding of the inhibitor within the protein's active or allosteric site. Additionally, the design of these inhibitors takes into account various physicochemical properties, such as molecular weight, lipophilicity, polarity, and solubility. Hydrophobic regions in the inhibitor structure may interact with non-polar regions of the protein, while polar or charged functional groups can form electrostatic or hydrogen-bonding interactions with polar residues. This balance of hydrophilic and hydrophobic properties is crucial for optimizing the binding affinity and stability of Trav12n-1 inhibitors in different biological environments, allowing for efficient modulation of the protein's function.
SEE ALSO...
Items 11 to 20 of 20 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic Acid, the active form of Mycophenolate mofetil, inhibits inosine monophosphate dehydrogenase, leading to a depletion of guanosine nucleotides and consequent inhibition of T-cell and B-cell proliferation. This would result in a reduced function of Trav12n-1 as it is likely involved in the adaptive immune response facilitated by these cells. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. As T-cells require pyrimidines for proliferation, inhibiting their synthesis with Leflunomide would result in reduced T-cell proliferation, thereby indirectly inhibiting the functional role of Trav12n-1 in immune responses. | ||||||
6-Thioguanine | 154-42-7 | sc-205587 sc-205587A | 250 mg 500 mg | $42.00 $54.00 | 3 | |
6-Thioguanine gets incorporated into DNA and RNA, disrupting their function and synthesis. It preferentially affects rapidly dividing cells, such as T-cells, thus indirectly inhibiting the function of Trav12n-1 by reducing the proliferation and function of T-cells. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, leading to a decrease in thymidine and consequently DNA synthesis. This affects rapidly dividing cells, including T-cells, which can indirectly inhibit the function of Trav12n-1 by reducing the availability of T-cells in the immune response. | ||||||
Aminopterin | 54-62-6 | sc-202461 | 50 mg | $102.00 | 1 | |
Aminopterin is a folate analog that inhibits dihydrofolate reductase, leading to a deficiency in tetrahydrofolate and subsequent inhibition of nucleotide biosynthesis. This affects T-cell proliferation and therefore indirectly inhibits the function of Trav12n-1 by limiting T-cell mediated immune responses. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Cyclophosphamide is an alkylating agent that cross-links DNA and RNA, leading to cell cycle arrest and apoptosis in proliferating cells. This action can indirectly inhibit the function of Trav12n-1 by reducing the number of proliferating T-cells that would express or require Trav12n-1 for immune responses. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine is a nucleotide analog that inhibits DNA polymerase and ribonucleotide reductase, leading to disruption of DNA synthesis and repair. This preferentially affects lymphocytes, thus indirectly inhibiting Trav12n-1 by reducing lymphocyte proliferation and function. | ||||||
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
Cladribine is a purine nucleoside analog that disrupts DNA synthesis and repair, leading to cell cycle arrest and apoptosis. It is particularly toxic to lymphocytes, thereby indirectly inhibiting the function of Trav12n-1 by reducing the population of T-cells. | ||||||
Pentostatin | 53910-25-1 | sc-204177 sc-204177A | 10 mg 50 mg | $175.00 $702.00 | 5 | |
Pentostatin inhibits adenosine deaminase, an enzyme crucial for purine metabolism. This results in toxic levels of deoxyadenosine for lymphocytes, leading to their apoptosis or malfunction. This indirectly inhibits Trav12n-1 by decreasing the T-cell count and impairing immune responses where Trav12n-1 would be involved. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that leads to the accumulation of misfolded proteins, causing cell cycle arrest and apoptosis | ||||||